Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Completed 9Unknown 2Terminated 2Recruiting 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 23Breast Carcinoma In Situ 3Ovarian Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Inflammatory Breast Neoplasms 1Endometrial Neoplasms 1Cardiotoxicity 1Carcinoma, Intraductal, Noninfiltrating 1Breast Cancer Metastatic 1Barrett Esophagus 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

pembrolizumab 30Capecitabine 24Bevacizumab 23Cyclophosphamide 22Gemcitabine 21Paclitaxel 20Nivolumab 19Fluorouracil 19Docetaxel 18aldesleukin 17Leucovorin 17Irinotecan 17Oxaliplatin 15Interleukin-2 14Radiosurgery 13Cisplatin 13Cetuximab 13fludarabine 12Carboplatin 12Albumin-Bound Paclitaxel 11fludarabine phosphate 10Ipilimumab 10Drug Therapy 10Doxorubicin 10Sunitinib 9Radiotherapy 9Everolimus 9130-nm albumin-bound paclitaxel 9Trastuzumab 8Temozolomide 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Neoplasm Metastasis × Tamoxifen × Clear all
NCT00684216 2017-09-14

Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer

The Netherlands Cancer Institute

Phase 2/3 Terminated
10 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT00532454 2010-02-10

Evaluation of the Association Between CYP2D6 Genetic Polymorphisms and the Treatment Effect of Tamoxifen

National Cancer Center, Korea

Phase 2 Terminated
21 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡